FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2964202410> ?p ?o ?g. }

• W2964202410 abstract "8598 Background: Functionally activating mutations (mut) in Gnaq or Gna11, genes that encode for widely expressed G-protein alpha subunits, are early oncogenic events in uveal melanoma (UM) development and result in activation of the MAPK pathway. We previously demonstrated effective pathway inhibition with selumetinib (AZD6244, ARRY-142866) in UM cell lines, with decreased viability associated with pERK and cyclinD1 suppression (Ambrosini, AACR 2010). Methods: Using paired metastatic tumor biopsies from patients (pts) with radiographically progressing UM treated with selumetinib 75 mg BID on a phase II trial (NCT01143402), we correlated MAPK pathway inhibition with radiographic tumor regression and clinical benefit. Biopsies were performed at baseline and after 14 +/-1 days of treatment. Western blotting was performed for pERK and cyclinD1, and quantitated by densitometry. Response (RECIST 1.1) was assessed at baseline, week (wk) 4, wk 8, and q8wks subsequently. Radiographic regression was defined as greatest percentage shrinkage from baseline. Clinical benefit was defined as RECIST response or stable disease ≥16wks. Results: Paired tumor biopsies were assayed from 18 pts: median age 60 (range 47-81), M:F 11:7, median 1 prior therapy (range 0-2), 17 with liver involvement, Gnaq mut:Gna11 mut:wild-type 8:9:1. Radiographic regression was observed in 5 pts, with 2 achieving partial responses. 4 pts were on study ≥16wks (16+, 20, 25, 31 wks), with one currently on study at 11+ wks. Median pERK and cyclinD1 as measured by densitometry decreased by 48% (p=.03) and 76% (p=.03), respectively. Radiographic regression correlated with suppression of pERK (Spearmen’s rank correlation; p=0.04) but not cyclinD1 (p=0.38). A trend towards pERK suppression correlating with clinical benefit was observed (p=.07) with each of the 5 pts achieving PR or SD ≥16wks having a decrease of ≥30% in pERK from baseline. Conclusions: Selumetinib can inhibit pERK and cyclinD1 in UM and can result in tumor shrinkage. Sustained inhibition of pERK inhibition at day 14 may be predictive of benefit. Further evaluation of MEK inhibition in this disease is warranted." @default.
• W2964202410 created "2019-07-30" @default.
• W2964202410 creator A5002965160 @default.
• W2964202410 creator A5006913373 @default.
• W2964202410 creator A5018352846 @default.
• W2964202410 creator A5019547481 @default.
• W2964202410 creator A5022347432 @default.
• W2964202410 creator A5026962347 @default.
• W2964202410 creator A5038396374 @default.
• W2964202410 creator A5043833554 @default.
• W2964202410 creator A5044132232 @default.
• W2964202410 creator A5045588395 @default.
• W2964202410 creator A5047847872 @default.
• W2964202410 creator A5054656505 @default.
• W2964202410 creator A5066373784 @default.
• W2964202410 creator A5067553501 @default.
• W2964202410 creator A5075497438 @default.
• W2964202410 creator A5083883593 @default.
• W2964202410 creator A5086473468 @default.
• W2964202410 creator A5089731384 @default.
• W2964202410 date "2012-05-20" @default.
• W2964202410 modified "2023-10-11" @default.
• W2964202410 title "Pharmacodynamic activity of selumetinib to predict radiographic response in advanced uveal melanoma." @default.
• W2964202410 doi "https://doi.org/10.1200/jco.2012.30.15_suppl.8598" @default.
• W2964202410 hasPublicationYear "2012" @default.
• W2964202410 type Work @default.
• W2964202410 sameAs 2964202410 @default.
• W2964202410 citedByCount "5" @default.
• W2964202410 countsByYear W29642024102014 @default.
• W2964202410 countsByYear W29642024102019 @default.
• W2964202410 crossrefType "journal-article" @default.
• W2964202410 hasAuthorship W2964202410A5002965160 @default.
• W2964202410 hasAuthorship W2964202410A5006913373 @default.
• W2964202410 hasAuthorship W2964202410A5018352846 @default.
• W2964202410 hasAuthorship W2964202410A5019547481 @default.
• W2964202410 hasAuthorship W2964202410A5022347432 @default.
• W2964202410 hasAuthorship W2964202410A5026962347 @default.
• W2964202410 hasAuthorship W2964202410A5038396374 @default.
• W2964202410 hasAuthorship W2964202410A5043833554 @default.
• W2964202410 hasAuthorship W2964202410A5044132232 @default.
• W2964202410 hasAuthorship W2964202410A5045588395 @default.
• W2964202410 hasAuthorship W2964202410A5047847872 @default.
• W2964202410 hasAuthorship W2964202410A5054656505 @default.
• W2964202410 hasAuthorship W2964202410A5066373784 @default.
• W2964202410 hasAuthorship W2964202410A5067553501 @default.
• W2964202410 hasAuthorship W2964202410A5075497438 @default.
• W2964202410 hasAuthorship W2964202410A5083883593 @default.
• W2964202410 hasAuthorship W2964202410A5086473468 @default.
• W2964202410 hasAuthorship W2964202410A5089731384 @default.
• W2964202410 hasConcept C111113717 @default.
• W2964202410 hasConcept C112705442 @default.
• W2964202410 hasConcept C121608353 @default.
• W2964202410 hasConcept C126322002 @default.
• W2964202410 hasConcept C126838900 @default.
• W2964202410 hasConcept C143998085 @default.
• W2964202410 hasConcept C2776087337 @default.
• W2964202410 hasConcept C2777658100 @default.
• W2964202410 hasConcept C2781187634 @default.
• W2964202410 hasConcept C36454342 @default.
• W2964202410 hasConcept C502942594 @default.
• W2964202410 hasConcept C526805850 @default.
• W2964202410 hasConcept C71924100 @default.
• W2964202410 hasConceptScore W2964202410C111113717 @default.
• W2964202410 hasConceptScore W2964202410C112705442 @default.
• W2964202410 hasConceptScore W2964202410C121608353 @default.
• W2964202410 hasConceptScore W2964202410C126322002 @default.
• W2964202410 hasConceptScore W2964202410C126838900 @default.
• W2964202410 hasConceptScore W2964202410C143998085 @default.
• W2964202410 hasConceptScore W2964202410C2776087337 @default.
• W2964202410 hasConceptScore W2964202410C2777658100 @default.
• W2964202410 hasConceptScore W2964202410C2781187634 @default.
• W2964202410 hasConceptScore W2964202410C36454342 @default.
• W2964202410 hasConceptScore W2964202410C502942594 @default.
• W2964202410 hasConceptScore W2964202410C526805850 @default.
• W2964202410 hasConceptScore W2964202410C71924100 @default.
• W2964202410 hasLocation W29642024101 @default.
• W2964202410 hasOpenAccess W2964202410 @default.
• W2964202410 hasPrimaryLocation W29642024101 @default.
• W2964202410 hasRelatedWork W100806778 @default.
• W2964202410 hasRelatedWork W1607072916 @default.
• W2964202410 hasRelatedWork W1972621047 @default.
• W2964202410 hasRelatedWork W2026299932 @default.
• W2964202410 hasRelatedWork W2051144764 @default.
• W2964202410 hasRelatedWork W2053520756 @default.
• W2964202410 hasRelatedWork W2169729757 @default.
• W2964202410 hasRelatedWork W2314229414 @default.
• W2964202410 hasRelatedWork W2326259093 @default.
• W2964202410 hasRelatedWork W2328143302 @default.
• W2964202410 hasRelatedWork W2427873479 @default.
• W2964202410 hasRelatedWork W2537317886 @default.
• W2964202410 hasRelatedWork W2547428353 @default.
• W2964202410 hasRelatedWork W2598525446 @default.
• W2964202410 hasRelatedWork W2619622310 @default.
• W2964202410 hasRelatedWork W2704415527 @default.
• W2964202410 hasRelatedWork W2796165638 @default.
• W2964202410 hasRelatedWork W2885934331 @default.
• W2964202410 hasRelatedWork W3138548440 @default.
• W2964202410 hasRelatedWork W3164187655 @default.
• W2964202410 isParatext "false" @default.
• W2964202410 isRetracted "false" @default.

• next